Journal Entry

JournalEntry

Ichose the Cystic Fibrosis Foundation since I am interested in leadingor managing a not-for-profit firm whose primary objective is toconduct research on incurable ailments. The foundation`s activitiesare mainly associated with the treatment of cystic fibrosiscondition. In addition, the firm strives to provide all patients withan opportunity to lead normal and productive lives. It funds variousresearch and drug improvement projects. For example, it is currentlyproviding financial support to 120 care centers and 53 associateprograms countrywide. A few years ago, CF patients did not live longenough to go to elementary school. Through the improvement inhealthcare providence, the foundation has helped people with thedisease to live longer. Approximately, all drugs that are currentlyused to treat the disease were developed as a result of thefoundation`s support.

CysticFibrosis Foundation is an excellent candidate for the strategicanalysis that I will perform for the final report since it is aninternational leader in the search for a cure for the disease.Furthermore, the firm is entirely endorsed by the Better BusinessBureau`s Wise Giving Alliance Program. Cystic Fibrosis Foundation hasidentified the significance of supporting skilled multidisciplinarycare groups to address the special needs of the cystic fibrosispatients. It motivates its volunteers and workers through awardingthem. Consequently, it has a well-performing board of trustees thatmakes sure the firm takes part in appropriate investments. Forexample, it sold its royalty rights in 2014 for CF treatmentdeveloped by Vertex for $3.3billion (Boyle,Bell, Konstan, McColley, Rowe &amp Rietschel, 2014).Cystic Fibrosis Foundation`s finance team utilizes the firm`s fundswell in an effort to finding a permanent cure to the disease.

References

Boyle,M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., &ampRietschel, E. (2014). A CFTR corrector (lumacaftor) and a CFTRpotentiator (ivacaftor) for treatment of patients with cysticfibrosis who have a phe508del CFTR mutation: a phase 2 randomisedcontrolled trial. TheLancet Respiratory Medicine.